secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indivior Pharmaceuticals, Inc. (INDV)
CIK:        0001625297
Form:       8-K
Filed at:   2026-01-08T23:59:59+00:00
Accession:  0001193125-26-006993
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Indivior provides FY2026 guidance: revenue $1.125B-$1.195B, Adj. EBITDA $535M-$575M
--------------------------------------------------------------------------------

- Total net revenue expected $1,125M-$1,195M; SUBLOCADE net revenue $905M-$945M.
- Non-GAAP operating expenses guided at $430M-$450M; adjusted EBITDA $535M-$575M.
- Completed Phase I of Indivior Action Agenda with annual operating expense savings of at least $150M.
- Shareholders approved U.K. to U.S. domicile change; expected effective Jan 26, 2026.
- Concluded DOJ matter by paying $295M in full; entered Phase II focused on accelerating growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625297/000119312526006993/0001193125-26-006993-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625297/000119312526006993/d74661d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-006993

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer